Recent Updates
Recently added Catalysts

CX501

Phase 2

EPIDERMOLYSIS BULLOSA | Small Molecules | Rare Disease |Takeda Pharmaceutical Company Limited|Trials Updated: Aug 1, 2019

CX501 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Sep 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

ACTIVE_CONTROLLED
Total Trials1
Total Enrollment12

FDA Designations

No designations recorded

CX501 clinical trials

CX501 · 1 trial · 1 indication

Phase 2 1
NCT00987142Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys BullosaEPIDERMOLYSIS BULLOSA
COMPLETED12 Analytics
PHASE2COMPLETED
Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa
EPIDERMOLYSIS BULLOSAUnlock trial analytics

Study Endpoints

Primary Endpoints

Time to epithelization
21 days

Secondary Endpoints

Fibroblast persistence
3, 8 and 12 months
Incidence of Adverse Events
12 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CX501EXPERIMENTALCultured chimeric skin
Non adherent dressingACTIVE_COMPARATOROcclusive non adherent dressing

Interventions

NameTypeDescription
CX501DRUGCultured chimeric skin
Occlusive non adherent dressingDEVICEApplication of an occlusive non adherent dressing in the skin donor site
Unlock Study Design Details

Eligibility Criteria

Age Range28 Days to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion criteria: * Patients of both sexes over 28 days of age. * Patients with recessive dystrophic epidermolysis bullosa diagnosed by clinical and historical criteria with severe skin syndactyly in whom reconstructive surgery is indicated. * Patients whose legal guardians have given written inf...

Countries:Spain
Unlock Eligibility Criteria

Frequently asked questions about CX501

What is CX501 used for?

CX501 is being developed for the treatment of epidermolysis bullosa, a rare genetic skin condition. It is a small molecule therapeutic candidate that Takeda Pharmaceutical Company Limited has studied in a Phase 2 clinical trial. The program targets a rare disease indication with high unmet medical need.

Who is developing CX501?

CX501 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor behind the clinical program evaluating CX501 in epidermolysis bullosa. The company is a global pharmaceutical developer with a portfolio spanning multiple therapeutic areas, including rare diseases.

What phase is CX501 in?

CX501 has completed a Phase 2 clinical trial in epidermolysis bullosa. It is an investigational therapy and is not approved for commercial use. The Phase 2 study has finished, and no active trials of CX501 are currently listed. Further development steps would depend on Takeda's program decisions.

What clinical trials has CX501 been studied in?

CX501 was evaluated in a single Phase 2 trial, NCT00987142, titled a trial to assess efficacy of a chimeric skin in patients with epidermolysis bullosa. The study enrolled 12 participants in Spain, included patients from 28 days of age, and used an active-controlled design. It is listed as completed.

How was the CX501 epidermolysis bullosa trial designed?

The CX501 Phase 2 trial, NCT00987142, was an active-controlled study that enrolled 12 patients with epidermolysis bullosa. It was not randomized and not double-blind, and it did not use biomarker selection. Participants were recruited in Spain, and the trial included both male and female patients starting at 28 days of age.